Lafayette Investments Inc. purchased a new stake in shares of Becton, Dickinson and Company (NYSE:BDX) during the first quarter, Holdings Channel reports. The institutional investor purchased 22,762 shares of the medical instruments supplier’s stock, valued at approximately $4,175,000.

A number of other institutional investors have also recently modified their holdings of the stock. Glassman Wealth Services increased its position in Becton, Dickinson and Company by 0.7% in the fourth quarter. Glassman Wealth Services now owns 854 shares of the medical instruments supplier’s stock valued at $141,000 after buying an additional 6 shares during the period. Wellington Shields & Co. LLC increased its position in Becton, Dickinson and Company by 0.3% in the first quarter. Wellington Shields & Co. LLC now owns 2,534 shares of the medical instruments supplier’s stock valued at $465,000 after buying an additional 8 shares during the period. Northstar Group Inc. increased its position in Becton, Dickinson and Company by 0.3% in the first quarter. Northstar Group Inc. now owns 2,985 shares of the medical instruments supplier’s stock valued at $550,000 after buying an additional 10 shares during the period. Sii Investments Inc. WI increased its position in Becton, Dickinson and Company by 0.7% in the fourth quarter. Sii Investments Inc. WI now owns 1,490 shares of the medical instruments supplier’s stock valued at $246,000 after buying an additional 11 shares during the period. Finally, Capital Investment Advisors LLC increased its position in Becton, Dickinson and Company by 0.7% in the first quarter. Capital Investment Advisors LLC now owns 2,412 shares of the medical instruments supplier’s stock valued at $442,000 after buying an additional 17 shares during the period. 75.47% of the stock is currently owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Shares of Becton, Dickinson and Company (NYSE BDX) opened at 191.29 on Friday. Becton, Dickinson and Company has a 12 month low of $161.29 and a 12 month high of $194.11. The company has a 50-day moving average of $187.33 and a 200 day moving average of $179.43. The company has a market cap of $40.80 billion, a PE ratio of 31.77 and a beta of 1.04.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Tuesday, May 2nd. The medical instruments supplier reported $2.30 earnings per share for the quarter, beating analysts’ consensus estimates of $2.23 by $0.07. The company had revenue of $2.97 billion for the quarter, compared to analyst estimates of $2.92 billion. Becton, Dickinson and Company had a return on equity of 25.37% and a net margin of 10.67%. The firm’s revenue for the quarter was down 3.2% on a year-over-year basis. During the same quarter last year, the firm posted $2.18 EPS. On average, analysts anticipate that Becton, Dickinson and Company will post $9.45 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 30th. Shareholders of record on Friday, June 9th will be issued a $0.73 dividend. The ex-dividend date is Wednesday, June 7th. This represents a $2.92 dividend on an annualized basis and a yield of 1.53%. Becton, Dickinson and Company’s payout ratio is currently 48.26%.

TRADEMARK VIOLATION WARNING: “Lafayette Investments Inc. Takes Position in Becton, Dickinson and Company (BDX)” was published by Financial Market News and is owned by of Financial Market News. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://www.financial-market-news.com/2017/06/17/lafayette-investments-inc-takes-position-in-becton-dickinson-and-company-bdx.html.

Several equities analysts have recently commented on the stock. Royal Bank Of Canada reissued a “hold” rating and issued a $177.00 target price on shares of Becton, Dickinson and Company in a report on Thursday, April 13th. Zacks Investment Research raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating and set a $206.00 target price on the stock in a report on Tuesday, April 11th. Jefferies Group LLC reissued a “buy” rating and issued a $200.00 target price on shares of Becton, Dickinson and Company in a report on Wednesday, March 29th. Finally, Evercore ISI raised shares of Becton, Dickinson and Company from an “in-line” rating to an “outperform” rating and boosted their target price for the stock from $186.00 to $200.00 in a report on Monday, April 24th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of $186.09.

In other Becton, Dickinson and Company news, VP Jeffrey S. Sherman sold 28,765 shares of the firm’s stock in a transaction on Thursday, May 25th. The stock was sold at an average price of $185.98, for a total value of $5,349,714.70. Following the completion of the sale, the vice president now directly owns 70,821 shares of the company’s stock, valued at approximately $13,171,289.58. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 1.40% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.